Posted in | News | Remote Monitoring

Dialysis Systems with Remote Monitoring Capabilities May Improve Patient Access to Home Therapy

Baxter International Inc. today presented data showing how innovative dialysis systems with new remote connectivity may improve patient access to home therapy. The data, presented at the 52nd Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), includes the perceptions of more than 500 healthcare providers and patients regarding the benefits associated with advanced automated peritoneal dialysis (APD) cyclers with remote monitoring capabilities of home patients (Abstract # FP586), and several abstracts supporting cost-effectiveness and utility of High Dose Hemodialysis (HD).

"Baxter’s focus is to understand and support access to the best renal replacement therapy options for every patient, whether it’s performed in the home or in-center,'' said Bruce Culleton, M.D., vice president, renal therapeutic area lead, Baxter. ''These data suggest new technologies may improve both physicians’ and patients’ experience and may reduce barriers to allow more patients to receive therapy in their home.''

Home therapy is an important and often underutilized dialysis option. Globally, approximately 13 percent of dialysis patients are on home dialysis therapy, with the remaining patients on in-center treatment.1

The APD cycler study reported on results of phone and web-based surveys with patients, nephrologists and renal nurses in the United Kingdom and the United States to gauge the importance and utility of a cycler with remote monitoring features compared with a cycler without remote monitoring capability. Of those surveyed, 86 percent of the healthcare providers agreed an APD cycler with remote patient monitoring capabilities will provide them more confidence and control when managing peritoneal dialysis (PD) patients. Patients also felt the new APD cycler may help reduce operator errors due to the user interface.

High Dose HD Home Therapy Assessed to be Cost-Effective

An additional study on the accessibility of home renal therapy included an analysis of the estimated cost-effectiveness attributable to High Dose HD. Because High Dose HD is performed more frequently, it is not typically performed in a clinic due to the high cost to administer. In an analysis of High Dose HD completed in the United Kingdom, Netherlands and France, High Dose HD at home was found to be cost-effective when compared to conventional in-center HD (ICHD) with the current reimbursement levels. However, High Dose HD when performed in-center versus ICHD was not cost-effective in France or the UK. This analysis also shows reimbursement could be raised to compensate providers for the increased costs and still maintain the efficiency to the relevant healthcare systems (Abstract #FP728).

Innovation Supports Individualized Care

Baxter recently completed CE marking (market approval) and unveiled the HOMECHOICE CLARIA APD system with SHARESOURCE at ERA-EDTA. SHARESOURCE, a remote monitoring system that allows healthcare professionals to deliver individualized patient care at home, is also available on the VIVIA hemodialysis system. The VIVIA hemodialysis system, designed to deliver High Dose HD therapy in the home, also completed the CE marking process in Europe in 2013. HOMECHOICE CLARIA, SHARESOURCE (web-based remote monitoring system) and the VIVIA system are currently not available in the United States.

''Baxter is dedicated to providing renal patients the best possible life by elevating the standards of care across all therapeutic options, whether that be in-center or home for chronic care, or in a hospital setting for acute care,'' said Jill Schaaf, president of Baxter’s Renal business. ''Our emphasis is on advancing innovation and supporting increased treatment options for ESRD patients and providers.''

ERA-EDTA presentations may be available on the congress website following the conclusion of the meeting. For more information, log on to

For prescription only. For safe and proper use of the devices mentioned herein, refer to the complete instructions in the Operator's Manual.

1 Data on file, Baxter International Inc., 2015.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Azthena logo powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.